Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital

Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effects of a single dose of psilocybin on behaviour, brain 5-HT2A receptor occupancy and gene expression in the pig

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Plasma psilocin critically determines behavioral and neurobiological effects of psilocybin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Imaging of the Serotonin System: Radiotracers and Applications in Memory Disorders

    Publikation: Bidrag til bog/antologi/rapportBidrag til bog/antologiUndervisning

  • Mathias E Jensen
  • Aurelio Galli
  • Morgane Thomsen
  • Kathrine L Jensen
  • Gerda K Thomsen
  • Mette K Klausen
  • Tina Vilsbøll
  • Mikkel B Christensen
  • Jens J Holst
  • Anthony Owens
  • Sabrina Robertson
  • Lynette Daws
  • Daniele Zanella
  • Ulrik Gether
  • Gitte M Knudsen
  • Anders Fink-Jensen
Vis graf over relationer

INTRODUCTION: A solid body of preclinical evidence shows that glucagon-like peptide-1 receptor (GLP-1R) agonists attenuate the effects of substance use disorder related behaviors. The mechanisms underlying these effects remain elusive. In the present study, we hypothesized that GLP-1R activation modulates dopaminetransporter (DAT) and thus dopamine (DA) homeostasis in striatum. This was evaluated in three different experiments: two preclinical and one clinical.

METHODS: Rat striatal DA uptake, DA clearance and DAT cell surface expression was assessed following GLP-1 (7-36)-amide exposure in vitro. DA uptake in mice was assesed ex vivo following systemic treatment with the GLP-1R agonist exenatide. In addition, DA uptake was measured in GLP-1R knockout mice and compared with DA-uptake in wild type mice. In healthy humans, changes in DAT availability was assessed during infusion of exenatide measured by single-photon emission computed tomography imaging.

RESULTS: In rats, GLP-1 (7-36)-amide increased DA uptake, DA clearance and DAT cell surface expression in striatum. In mice, exenatide did not change striatal DA uptake. In GLP-1R knockout mice, DA uptake was similar to what was measured in wildtype mice. In humans, systemic infusion of exenatide did not result in acute changes in striatal DAT availability.

CONCLUSIONS: The GLP-1R agonist-induced modulation of striatal DAT activity in vitro in rats could not be replicated ex vivo in mice and in vivo in humans. Therefore, the underlying mechanisms of action for the GLP-1R agonists-induced efficacy in varios addiction-like behavioural models still remain.

TidsskriftNeurochemistry International
Sider (fra-til)104772
StatusUdgivet - 1 sep. 2020

Bibliografisk note

Copyright © 2020 Elsevier Ltd. All rights reserved.

ID: 60286956